Ziyuglycoside II-induced apoptosis in human gastric carcinoma BGC-823 cells by regulating Bax/Bcl-2 expression and activating caspase-3 pathway

Brazilian Journal of Medical and Biological Research

Volumn 46, Issue 8, 2013, Pages 670-675

  Zhu, A K ^a   Zhou, H ^a   Xia, J Z ^a   Jin, H C ^a   Wang, K ^b   Yan, J ^a   Zuo, J B ^a   Zhu, X ^b   Shan, T ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

Author keywords

Apoptosis; Bax Bcl 2; BGC 823 cells; Caspase 3; Ziyuglycoside II

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; FLUOROURACIL; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG; ZIYUGLYCOSIDE II;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL GROWTH; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; STOMACH CARCINOMA; WESTERN BLOTTING;

SANGUISORBA OFFICINALIS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA; CASPASE 3; CASPASE INHIBITORS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FLUOROMETRY; FLUOROURACIL; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; SANGUISORBA; SAPONINS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84883497442     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20133050     Document Type: Article

References (24)

1. Yeoh KG. How do we improve outcomes for gastric cancer? J Gastroenterol Hepatol 2007; 22: 970-972, doi: 10.1111/j. 1440-1746.2007.04956.x.
2. Smyth EC, Cunningham D. Targeted therapy for gastric cancer. Curr Treat Options Oncol 2012; 13: 377-389, doi:10.1007/s11864-012-0192-6.
3. Power DG, Kelsen DP, Shah MA. Advanced gastric cancer-slow but steady progress. Cancer Treat Rev 2010; 36: 384-392, doi: 10.1016/j.ctrv.2010.01.005.
4. Gill RS, Al-Adra DP, Nagendran J, Campbell S, Shi X, Haase E, et al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol 2011; 104: 692-698, doi: 10.1002/jso.22017.
5. Zhang D, Fan D. Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges. Expert Rev Anticancer Ther 2007; 7: 1369-1378, doi: 10.1586/14737140.7.10.1369.
6. Zhang D, Fan D. New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives. Future Oncol 2010; 6: 527-537, doi: 10.2217/fon.10.21.
7. Chen S, Flower A, Ritchie A, Liu J, Molassiotis A, Yu H, et al. Oral Chinese herbal medicine (CHM) as an adjuvant treatment during chemotherapy for non-small cell lung cancer: A systematic review. Lung Cancer 2010; 68: 137-145, doi: 10.1016/j.lungcan.2009.11.008.
8. Wu T, Yang X, Zeng X, Eslick GD. Traditional Chinese medicinal herbs in the treatment of patients with esophageal cancer: a systematic review. Gastroenterol Clin North Am 2009; 38: 153-167, x, doi: 10.1016/j.gtc.2009.01.006.
9. Molassiotis A, Potrata B, Cheng KK. A systematic review of the effectiveness of Chinese herbal medication in symptom management and improvement of quality of life in adult cancer patients. Complement Ther Med 2009; 17: 92-120, doi: 10.1016/j.ctim.2008.11.002.
10. Lee NH, Lee MY, Lee JA, Jung DY, Seo CS, Kim JH, et al. Anti-asthmatic effect of Sanguisorba officinalis L. and potential role of heme oxygenase-1 in an ovalbumininduced murine asthma model. Int J Mol Med 2010; 26: 201-208.
11. Zhang S, Liu X, Zhang ZL, He L, Wang Z, Wang GS. Isolation and identification of the phenolic compounds from the roots of Sanguisorba officinalis L. and their antioxidant activities. Molecules 2012; 17: 13917-13922, doi: 10.3390/ molecules171213917.
12. Choi ES, Kim JS, Kwon KH, Kim HS, Cho NP, Cho SD. Methanol extract of Sanguisorba officinalis L. with cytotoxic activity against PC3 human prostate cancer cells. Mol Med Rep 2012; 6: 670-674.
13. Cai Z, Li W, Wang H, Yan W, Zhou Y, Wang G, et al. Antitumor and immunomodulating activities of a polysaccharide from the root of Sanguisorba officinalis L. Int J Biol Macromol 2012; 51: 484-488, doi: 10.1016/j.ijbiomac.2012.05.029.
14. Wang Z, Loo WT, Wang N, Chow LW, Wang D, Han F, et al. Effect of Sanguisorba officinalis L on breast cancer growth and angiogenesis. Expert Opin Ther Targets 2012; 16 (Suppl 1): S79-S89, doi: 10.1517/14728222.2011.642371.
15. Kim YH, Chung CB, Kim JG, Ko KI, Park SH, Kim JH, et al. Anti-wrinkle activity of ziyuglycoside I isolated from a Sanguisorba officinalis root extract and its application as a cosmeceutical ingredient. Biosci Biotechnol Biochem 2008; 72: 303-311, doi: 10.1271/bbb.70268.
16. Kirkin V, Joos S, Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 2004; 1644: 229-249, doi: 10.1016/j.bbamcr.2003.08.009.
17. Mishra BB, Tiwari VK. Natural products: an evolving role in future drug discovery. Eur J Med Chem 2011; 46: 4769-4807, doi: 10.1016/j.ejmech.2011.07.057.
18. Manion MK, Hockenbery DM. Targeting BCL-2-related proteins in cancer therapy. Cancer Biol Ther 2003; 2: S105-S114.
19. Jendrossek V. The intrinsic apoptosis pathways as a target in anticancer therapy. Curr Pharm Biotechnol 2012; 13: 1426-1438, doi: 10.2174/138920112800784989.
20. Ott M, Norberg E, Zhivotovsky B, Orrenius S. Mitochondrial targeting of tBid/Bax: a role for the TOM complex? Cell Death Differ 2009; 16: 1075-1082, doi: 10.1038/cdd.2009.61.
21. Selvakumaran M, Lin HK, Miyashita T, Wang HG, Krajewski S, Reed JC, et al. Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways. Oncogene 1994; 9: 1791-1798.
22. Snigdha S, Smith ED, Prieto GA, Cotman CW. Caspase-3 activation as a bifurcation point between plasticity and cell death. Neurosci Bull 2012; 28: 14-24, doi: 10.1007/s12264-012-1057-5.
23. Sawada M, Nakashima S, Banno Y, Yamakawa H, Hayashi K, Takenaka K, et al. Ordering of ceramide formation, caspase activation, and Bax/Bcl-2 expression during etoposide-induced apoptosis in C6 glioma cells. Cell Death Differ 2000; 7: 761-772, doi: 10.1038/sj.cdd.4400711.
24. Hoshyar R, Bathaie SZ, Sadeghizadeh M. Crocin triggers the apoptosis through increasing the Bax/Bcl-2 ratio and caspase activation in human gastric adenocarcinoma, AGS, cells. DNA Cell Biol 2013; 32: 50-57, doi: 10.1089/dna.2012.1866.